317 related articles for article (PubMed ID: 35595166)
21. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
22. KRAS G12C fragment screening renders new binding pockets.
Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R
Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391
[TBL] [Abstract][Full Text] [Related]
23. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
24. Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S; Gurbani D; Du G; Everley RA; Browne CM; Chaikuad A; Tan L; Schröder M; Gondi S; Ficarro SB; Sim T; Kim ND; Berberich MJ; Knapp S; Marto JA; Westover KD; Sorger PK; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):818-829.e9. PubMed ID: 30982749
[TBL] [Abstract][Full Text] [Related]
25. Modeling receptor flexibility in the structure-based design of KRAS
Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
[TBL] [Abstract][Full Text] [Related]
26. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
27. Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.
Wang L; Zhao J; Yao Y; Wang C; Zhang J; Shu X; Sun X; Li Y; Liu K; Yuan H; Ma X
Eur J Med Chem; 2017 Dec; 142():493-505. PubMed ID: 28986130
[TBL] [Abstract][Full Text] [Related]
28. Covalent inhibitors of the GTPase KRAS
Kettle JG; Cassar DJ
Expert Opin Ther Pat; 2020 Feb; 30(2):103-120. PubMed ID: 31913776
[No Abstract] [Full Text] [Related]
29. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
[TBL] [Abstract][Full Text] [Related]
30. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
32. Drugging the Ral GTPase.
Yan C; Jones DN; Theodorescu D
Small GTPases; 2015; 6(3):157-9. PubMed ID: 26280620
[TBL] [Abstract][Full Text] [Related]
33. Approach in Improving Potency and Selectivity of Kinase Inhibitors: Allosteric Kinase Inhibitors.
Wei S; Zhao T; Wang J; Zhai X
Mini Rev Med Chem; 2021; 21(8):991-1003. PubMed ID: 33355051
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
Khan I; Rhett JM; O'Bryan JP
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
[TBL] [Abstract][Full Text] [Related]
35. Cysteinome: The first comprehensive database for proteins with targetable cysteine and their covalent inhibitors.
Wu S; Luo Howard H; Wang H; Zhao W; Hu Q; Yang Y
Biochem Biophys Res Commun; 2016 Sep; 478(3):1268-73. PubMed ID: 27553277
[TBL] [Abstract][Full Text] [Related]
36. Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors.
Zain R; Vihinen M
Front Immunol; 2021; 12():694853. PubMed ID: 34349760
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Nonfunctional Ras.
Nussinov R; Jang H; Gursoy A; Keskin O; Gaponenko V
Cell Chem Biol; 2021 Feb; 28(2):121-133. PubMed ID: 33440168
[TBL] [Abstract][Full Text] [Related]
38. Probing RAS Function with Monobodies.
Khan I; O'Bryan JP
Methods Mol Biol; 2021; 2262():281-302. PubMed ID: 33977484
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
40. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD
Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]